NASDAQ:COCP Cocrystal Pharma (COCP) Stock Forecast, Price & News $2.22 -0.01 (-0.45%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.17▼$2.3050-Day Range$1.80▼$2.8152-Week Range$1.74▼$6.24Volume27,008 shsAverage Volume67,644 shsMarket Capitalization$22.58 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cocrystal Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside440.5% Upside$12.00 Price TargetShort InterestHealthy0.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 3 Articles This WeekInsider TradingAcquiring Shares$2 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.13) to ($1.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector198th out of 983 stocksPharmaceutical Preparations Industry85th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Cocrystal Pharma has a forecasted upside of 440.5% from its current price of $2.22.Amount of Analyst CoverageCocrystal Pharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.54% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cocrystal Pharma has recently decreased by 13.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COCP. Previous Next 1.6 News and Social Media Coverage News SentimentCocrystal Pharma has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cocrystal Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for COCP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cocrystal Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,000,001.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Cocrystal Pharma is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cocrystal Pharma are expected to grow in the coming year, from ($2.13) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cocrystal Pharma (NASDAQ:COCP) StockCocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.Read More Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address COCP Stock News HeadlinesMay 31, 2023 | finance.yahoo.comCocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988May 26, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Cocrystal Pharma, Inc. Decreased by HC Wainwright (NASDAQ:COCP)June 3, 2023 | Behind the Markets (Ad)"How war impacts the stock market"Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your RetirementMay 26, 2023 | americanbankingnews.comCocrystal Pharma (NASDAQ:COCP) Given New $12.00 Price Target at HC WainwrightMay 24, 2023 | msn.comHC Wainwright & Co. Maintains Cocrystal Pharma (COCP) Buy RecommendationMay 24, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Cocrystal Pharma (COCP)May 17, 2023 | finance.yahoo.comCOCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline.May 15, 2023 | finance.yahoo.comCocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsJune 3, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See The True Value of Any StockGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 4, 2023 | finance.yahoo.comCocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group ConferenceApril 24, 2023 | finance.yahoo.comCocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of DirectorsApril 18, 2023 | finance.yahoo.comCocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group ConferenceApril 15, 2023 | americanbankingnews.comFibroGen (NASDAQ:FGEN) versus Cocrystal Pharma (NASDAQ:COCP) Head-To-Head ContrastApril 12, 2023 | benzinga.comCocrystal Pharma Inc (COCP) Up 15.54% in Premarket TradingApril 10, 2023 | msn.comWhy Cocrystal Pharma Shares Are Trading Higher TodayApril 10, 2023 | finance.yahoo.comCocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesApril 9, 2023 | americanbankingnews.comInsider Buying: Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Purchases 1,015,229 Shares of StockApril 7, 2023 | americanbankingnews.comCocrystal Pharma, Inc. (NASDAQ:COCP) Forecasted to Post Q1 2023 Earnings of ($0.55) Per ShareApril 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Cocrystal Pharma (COCP)March 30, 2023 | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP)March 29, 2023 | finance.yahoo.comCocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development ProgramsMarch 29, 2023 | americanbankingnews.comCocrystal Pharma, Inc. to Post FY2022 Earnings of ($2.41) Per Share, Zacks Small Cap Forecasts (NASDAQ:COCP)March 22, 2023 | finance.yahoo.comCOCP: UPDATE: Cocrystal Pharma announced several program updates and investor events.March 22, 2023 | finance.yahoo.comCocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023January 27, 2023 | seekingalpha.comCOCP Cocrystal Pharma, Inc.January 26, 2023 | finance.yahoo.comCocrystal Pharma Announces Participation in Virtual Investor EventsJanuary 23, 2023 | finance.yahoo.comCocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day PodcastSee More Headlines COCP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COCP Company Calendar Last Earnings3/29/2023Today6/03/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COCP CUSIPN/A CIK1412486 Webwww.cocrystalpharma.com Phone(305) 425-1780FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+440.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.8912) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.66% Return on Assets-43.29% Debt Debt-to-Equity RatioN/A Current Ratio11.84 Quick Ratio11.84 Sales & Book Value Annual Sales$2.01 million Price / Sales11.23 Cash Flow$0.17 per share Price / Cash Flow13.14 Book Value$3.41 per share Price / Book0.65Miscellaneous Outstanding Shares10,170,000Free Float9,614,000Market Cap$22.58 million OptionableNot Optionable Beta1.20 Key ExecutivesSam LeePresident & Co-Chief Executive OfficerJames Joseph MartinCo-Chief Executive Officer, CFO & SecretaryLuz PascualVice President-Clinical DevelopmentKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXVaccinexNASDAQ:VCNXEquilliumNASDAQ:EQOnconova TherapeuticsNASDAQ:ONTXLiminal BioSciencesNASDAQ:LMNLView All CompetitorsInsiders & InstitutionsSabby Management LLCSold 354,538 shares on 5/16/2023Ownership: 0.650%Susquehanna International Group LLPBought 20,728 shares on 5/16/2023Ownership: 0.204%Renaissance Technologies LLCBought 5,800 shares on 5/12/2023Ownership: 1.178%Phillip Md Et Al FrostBought 1,015,229 shares on 4/4/2023Total: $2.00 M ($1.97/share)View All Insider TransactionsView All Institutional Transactions COCP Stock - Frequently Asked Questions Should I buy or sell Cocrystal Pharma stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COCP shares. View COCP analyst ratings or view top-rated stocks. What is Cocrystal Pharma's stock price forecast for 2023? 1 equities research analysts have issued 1-year price objectives for Cocrystal Pharma's stock. Their COCP share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 440.5% from the stock's current price. View analysts price targets for COCP or view top-rated stocks among Wall Street analysts. How have COCP shares performed in 2023? Cocrystal Pharma's stock was trading at $1.95 at the beginning of the year. Since then, COCP shares have increased by 13.8% and is now trading at $2.22. View the best growth stocks for 2023 here. Are investors shorting Cocrystal Pharma? Cocrystal Pharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 34,100 shares, a decrease of 13.7% from the April 30th total of 39,500 shares. Based on an average trading volume of 70,200 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company's shares are sold short. View Cocrystal Pharma's Short Interest. When is Cocrystal Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our COCP earnings forecast. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.17. When did Cocrystal Pharma's stock split? Cocrystal Pharma shares reverse split on the morning of Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI). What is Cocrystal Pharma's stock symbol? Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP." Who are Cocrystal Pharma's major shareholders? Cocrystal Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.18%), Sabby Management LLC (0.65%) and Susquehanna International Group LLP (0.20%). Insiders that own company stock include Phillip Md Et Al Frost, Raymond F Schinazi and Richard C Pfenniger, Jr. View institutional ownership trends. How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cocrystal Pharma's stock price today? One share of COCP stock can currently be purchased for approximately $2.22. How much money does Cocrystal Pharma make? Cocrystal Pharma (NASDAQ:COCP) has a market capitalization of $22.58 million and generates $2.01 million in revenue each year. The company earns $-38,840,000.00 in net income (profit) each year or ($4.8912) on an earnings per share basis. How can I contact Cocrystal Pharma? Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The official website for the company is www.cocrystalpharma.com. The company can be reached via phone at (305) 425-1780 or via email at cocp@jtcir.com. This page (NASDAQ:COCP) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.